Epidemiologic Study of Persistent Polyclonal B-cell Lymphocytosis (PPBL)

Persistent Polyclonal B-Cell Lymphocytosis Clinical Trial

— LPLB  

Official title:

Epidemiologic Study of Persistent Polyclonal B-cell Lymphocytosis (PPBL) - Observatory 1990-2012

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03296046
• Other study ID #: 2011/PSS/LPLB/LESESVE//MS
• Status: Completed
• Phase: N/A
• First received: September 22, 2017
• Last updated: September 27, 2017
• Start date: November 13, 2012
• Est. completion date: December 31, 2015

Study information

• Verified date: September 2017
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main purpose of this study is the description of all French cases of PPBL and the establishment of minimal criteria for the pathology diagnosis and its follow-up.

The secondary objective is the immunologic and genetic characterization of lymphoid cells causing the disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 31, 2015
• Est. primary completion date: December 31, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• PPBL diagnosis established during a previous medical visit

Exclusion Criteria:

Related Conditions & MeSH terms

• Lymphocytosis
• Persistent Polyclonal B-Cell Lymphocytosis

Intervention

Biological:
• Blood test
30 ml

Locations

Country	Name	City	State
France	group GFHC and intergroup LLC (GCFLL-MW / GOELAMS)	Marseille
France	CHRU de Nancy - Hopitaux de Brabois	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relevant medical history		Baseline
Primary	Complete blood count		Baseline
Primary	Administration of first-line treatment or not		Baseline
Secondary	Lymphocyte phenotype		Baseline